Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Receivables (2022 - 2025)

Voyager Therapeutics' Receivables history spans 4 years, with the latest figure at $1.9 million for Q4 2025.

  • For Q4 2025, Receivables fell 12.29% year-over-year to $1.9 million; the TTM value through Dec 2025 reached $1.9 million, down 12.29%, while the annual FY2025 figure was $1.9 million, 12.29% down from the prior year.
  • Receivables for Q4 2025 was $1.9 million at Voyager Therapeutics, down from $4.0 million in the prior quarter.
  • Across five years, Receivables topped out at $83.5 million in Q4 2023 and bottomed at $1.9 million in Q4 2025.
  • The 4-year median for Receivables is $3.5 million (2024), against an average of $14.4 million.
  • The largest annual shift saw Receivables crashed 97.39% in 2024 before it fell 12.29% in 2025.
  • A 4-year view of Receivables shows it stood at $10.2 million in 2022, then skyrocketed by 716.54% to $83.5 million in 2023, then plummeted by 97.39% to $2.2 million in 2024, then dropped by 12.29% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Receivables are $1.9 million (Q4 2025), $4.0 million (Q3 2025), and $2.5 million (Q2 2025).